Results
In total 17 individual interviews and eight FGD were included in this analysis. Among them, 33 PROMISE-EPI participants, eight PROMISE-EPI staff and nine HCP including nurses, counselors, lab technicians and a pharmacist participated.The baseline characteristics of the PROMISE-EPI participants interviewed are described in Comparison of baseline characteristics between lamivudine-eligible PROMISE-EPI participants who were interviewed or not interviewed.The PROMISE-EPI identifier was not recorded for one PROMISE-EPI participant. ART: antiretroviral treatment; ARV: antiretroviral; AZT: zidovudine; 3TC: lamivudine; EFV: efavirenz; LPVr: lopinavir/ritonavir; DTG: dolutegravir; TDF: tenofovir; PNP: post-natal prophylaxis.The children and infants were between 6 and 18 months old at the time of these interviews.